Abstract
Background:
Immune checkpoint inhibitors (ICI) are a fast growing therapy used in several types of malignancies. The majority of immune related adverse events observed in the kidney are due to acute interstitial nephritis. Glomerular diseases although less common have also been described.
Case Presentation:
We present a case of phospholipase A2 receptor positive membranous nephropathy triggered by ICI therapy cemiplimab (PD1 inhibitor) in a 88 year old man with no prior history of proteinuria or glomerular disease. The patient responded to steroid monotherapy with rapid clinical and immunological remission.
Conclusion:
While patients undergoing ICI therapy warrant close monitoring of systemic immune related adverse events, physicians should remain vigilant of kidney related events and obtain a kidney biopsy if clinically indicated.
Get full access to this article
View all access options for this article.